May 4, 2009 (FinancialWire) — Pharmaceutical firm SuperGen, Inc. (NASDAQ: SUPG) (Current Market Cap: US$117.58 Mil.) chief medical officer, Gregory Berk, has left the company, which has launched a global search for his replacement.

Michael D. Young, a current member of the SuperGen board who serves as chairman and chief scientific officer of strategic healthcare development, will serve as interim chief medical advisor, consulting to company CEO James S. J. Manuso.

Manuso will oversee both clinical and regulatory development until a replacement for Berk can be found.

Based in Dublin, California-based SuperGen is a pharmaceutical company focused on the discovery and development of novel cancer therapies. The company is developing therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.